At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
SB-705498 +2 moredrug
Likely dose
SB-705498 12mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Incomplete Block, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of SB-705498 When Administered Alone or in Conjunction With Intranasal Fluticasone Propionate on the Symptoms of Rhinitis in the Vienna Allergen Challenge Chamber
In Brief
A Phase 2 clinical trial evaluating SB-705498, FP, and 1 other intervention for Rhinitis. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms induced by an allergen chamber challenge.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis
CountriesAustria
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
Primary CompletionJul 2011
First PostedAug 2011
TodayJul 2026
First PostedAug 29, 2011
Enrollment StartApr 14, 2011
Primary CompletionJul 7, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.8 years ago
Interventions
SB-705498drug
12mg intranasal
FPdrug
200ug intranasal
placebodrug
placebo intranasal